“LL-37”的搜索结果，显示 51-60 项，共有 6704 项

1. 乳腺专科门诊- 临床试验- 妙佑医疗国际

   This is a phase 1b/2 study of the safety and efficacy of MLN0128 in combination with exemestane or fulvestrant therapy in women with estrogen receptor ...

2. 神经科- 临床试验- 妙佑医疗国际

   Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...

3. 神经科- 临床试验- 妙佑医疗国际

   ... 2 or 3 meningioma as measured by 6-month PFS rate. A Study to Investigate Biomarkers for Phenotyping of Neurodegenerative Disorders. Jacksonville, Fla. The ...

4. 神经科- 临床试验- 妙佑医疗国际

   ... 2 or 3 meningioma as measured by 6-month PFS rate. A Study of Demyelinating ... (2) Cohort 2 focuses on primary or secondary myelofibrosis (MF) ...

5. 脑肿瘤项目- 临床试验- 妙佑医疗国际

   ... 2-year progression free survival (PFS) rate as compared to ACNS0122. ... Go to page 22 · Go to page 33 · Go to page 44 · NextNext Page · 申请预约 · 专长与排名 ...

6. 神经科- 临床试验- 妙佑医疗国际

   ... (2) Cohort 2 focuses on primary or secondary myelofibrosis (MF) displaying mutated calreticulin (muCALR); (3) Cohort 3 focuses on glioblastoma multiforme ...

7. 神经科- 临床试验- 妙佑医疗国际

   ... (2) Cohort 2 focuses on primary or secondary myelofibrosis (MF) displaying mutated calreticulin (muCALR); (3) Cohort 3 focuses on glioblastoma multiforme ...

8. 放射科- 临床试验- 妙佑医疗国际

   Go to page 22 · Go to page 33 · Go to page 44 · Go to page 55 · NextNext Page. 以下为当前的临床试验。 78 研究放射科（仅限开放性研究）. 按位置、状态和其他条件 ...

9. 神经科- 临床试验- 妙佑医疗国际

   ... 2 or 3 meningioma as measured by 6-month PFS rate. Validation Of Early Prognostic Data For Recovery Outcome After Stroke For Future, Higher Yield Trials.

10. 神经科- 临床试验- 妙佑医疗国际

    ... (2) Cohort 2 focuses on primary or secondary myelofibrosis (MF) displaying mutated calreticulin (muCALR); (3) Cohort 3 focuses on glioblastoma multiforme ...